Gyre Therapeutics, Inc.
GYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001124105
No open-market purchases or sales by Gyre Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Gyre Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 48 | 48 | 0 |
| Shares | 3.41M | 3.10M | −314.1K (−9.2%) |
| Value | $25.1M | $23.1M | −$1.97M (−7.9%) |
New holders (10)
Institutions that held Gyre Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 35,751 | $266.7K | 0.00% |
| Goldman Sachs Group Inc | 18,034 | $134.5K | 0.00% |
| Lazard Asset Management LLC | 14,932 | $111.4K | 0.00% |
| Jane Street Group, LLC | 12,958 | $96.7K | 0.00% |
| State of Alaska, Department of Revenue | 5,219 | $38.0K | 0.00% |
| Russell Investments Group, Ltd. | 1,124 | $8.38K | 0.00% |
| Optiver Holding B.V. | 222 | $1.66K | 0.00% |
| Simplex Trading, LLC | 164 | $1.00K | 0.00% |
| Advisory Services Network, LLC | 66 | $492 | 0.00% |
| SRS Capital Advisors, Inc. | 57 | $426 | 0.00% |
Sold out (10)
Institutions that held Gyre Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Susquehanna International Group, LLP | 35,912 | $264.0K |
| Nuveen, LLC | 17,594 | $129.3K |
| Verition Fund Management LLC | 13,345 | $98.1K |
| American Century Companies Inc | 11,291 | $83.0K |
| Aster Capital Management (DIFC) Ltd | 1,447 | $10.6K |
| Raymond James Financial Inc | 650 | $4.78K |
| GAMMA Investing LLC | 124 | $911 |
| Rise Advisors, LLC | 54 | $397 |
| Essential Partners LLC | 2 | $15 |
| IFP Advisors, Inc | 1 | $7 |